

Product datasheet for TL313244V

EIF4E Human shRNA Lentiviral Particle (Locus ID 1977)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	EIF4E Human shRNA Lentiviral Particle (Locus ID 1977)
Locus ID:	1977
Synonyms:	AUTS19; CBP; eIF-4E; EIF4E1; EIF4EL1; EIF4F
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	EIF4E - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
RefSeq:	<u>NM 001130678</u> , <u>NM 001130679</u> , <u>NM 001331017</u> , <u>NM 001968</u> , <u>NM 001968.1</u> , <u>NM 001968.2</u> , <u>NM 001968.3</u> , <u>NM 001968.4</u> , <u>NM 001130678.1</u> , <u>NM 001130678.2</u> , <u>NM 001130679.1</u> , <u>NM 001130679.2</u> , <u>BC035166</u> , <u>BC035166.1</u> , <u>BC012611</u> , <u>BC043226</u> , <u>BC107715</u> , <u>BM849222</u> , <u>NM 001130678.3</u>
UniProt ID:	<u>P06730</u>
Summary:	The protein encoded by this gene is a component of the eukaryotic translation initiation factor 4F complex, which recognizes the 7-methylguanosine cap structure at the 5' end of messenger RNAs. The encoded protein aids in translation initiation by recruiting ribosomes to the 5'-cap structure. Association of this protein with the 4F complex is the rate-limiting step in translation initiation. This gene acts as a proto-oncogene, and its expression and activation is associated with transformation and tumorigenesis. Several pseudogenes of this gene are found on other chromosomes. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2015]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u> . If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u> .



This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2022 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

STATES CALL CONTRACTOR STATES CONTRACTOR STREAM STATES STATES STREAM ST

Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).

This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2022 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US